Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 Adjuvant

The adjuvant AS03 is stockpiled for future formulations with new and existing vaccines for the control of pandemic influenza virus. We previously reported the immunogenicity of an A/H5N1 vaccine extemporaneously mixed with the AS03 adjuvant for 42 days following vaccination. This report extends thos...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Vaccine Immunol
Hauptverfasser: Chen, Wilbur H., Jackson, Lisa A., Edwards, Kathryn M., Keitel, Wendy A., Hill, Heather, Noah, Diana L., Creech, C. Buddy, Patel, Shital M., Mangal, Brian, Kotloff, Karen L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: American Society for Microbiology 2016
Schlagworte:
Vaccines
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4711091/
https://ncbi.nlm.nih.gov/pubmed/26561390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00475-15
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge